Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | MAX | P61244 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646425 | 0.93 | MYC (0.44) | MYCMAXL3MBTL1CTSVCTSL | |
| SCHEMBL6373099 | 0.92 | MYC (0.52) | MYCMAXCTSVCTSLCYP19A1 | |
| SCHEMBL6373720 | 0.87 | MYC (0.50) | MYCMAXL3MBTL1CTSVCTSL | |
| SCHEMBL6373712 | 0.87 | MYC (0.50) | MYCMAXL3MBTL1CTSVCTSL | |
| SCHEMBL12710192 | 0.85 | L3MBTL1 (0.46) | L3MBTL1LMNARAB9AALDH1A1HTT | |
| SCHEMBL6592919 | 0.84 | MYC (0.50) | MYCMAXL3MBTL1CTSVCTSL | |
| SCHEMBL9606830 | 0.83 | ALDH1A1 (0.40) | L3MBTL1CTSVCTSLLMNARAB9A | |
| SCHEMBL6592493 | 0.82 | MYC (0.53) | MYCMAXL3MBTL1CTSVCTSL | |
| SCHEMBL14626974 | 0.82 | L3MBTL1 (0.52) | L3MBTL1LMNAALDH1A1MAPTMEN1 | |
| SCHEMBL6592914 | 0.82 | MYC (0.53) | MYCMAXCTSVCTSLCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| EP-3856176-A2 | INHIBITORS OF VAP-1 | Acucela Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164454-A | Inhibitors of VAP-1 | 奥克塞拉有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020069330-A2 | INHIBITORS OF VAP-1 | ACUCELA INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | MYC 1620/4885MAX 3849/4885L3MBTL1 1029/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | MYC 1620/4885MAX 3849/4885L3MBTL1 1029/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | MYC 1233/4885MAX 2742/4885L3MBTL1 668/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | MYC 1620/4885MAX 3849/4885L3MBTL1 1029/4885 |
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | MYC 1620/4885MAX 3849/4885L3MBTL1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.